Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale
The Centamine scale holds promise for the harmonized quantification of dopaminergic neuronal imaging markers. The Centamine strategy would enable and accelerate clinical trials in Parkinson's disease using dopaminergic imaging outcomes. ANN NEUROL 2026;99:949-963.
Authors
- Gaia Rizzo (ORCID: https://orcid.org/0000-0001-7272-8576)
- Patrick Cella (ORCID: https://orcid.org/0009-0006-4333-1178)
- Robert A. Comley (ORCID: https://orcid.org/0000-0001-7546-5492)
- Gilles Tamagnan
- Justin M. Albani
- John Seibyl (ORCID: https://orcid.org/0000-0002-4917-5413)
- Leonardo Iaccarino
- Roger N. Gunn (ORCID: https://orcid.org/0000-0003-1181-5769)
- Adam James Schwarz (ORCID: https://orcid.org/0000-0002-9743-6171)
- Gregory Klein
- Ken Marek
- Zhen Fan
- Cristian Salinas
- Jamie Eberling
- Luca Passamonti
- Graham Searle
- The Parkinson's Progression Markers Initiative
Institutions
- Roche (Switzerland) (CH)
- Eli Lilly (United States) (US)
- General Electric (Spain) (ES)
- Michael J. Fox Foundation (US)
- AbbVie (United States) (US)
- Institute for Neurodegenerative Disorders (US)
- Lantheus Medical Imaging (United States) (US)
- Laboratoire d’Imagerie Biomédicale (FR)
- Mitsubishi Corporation (United Kingdom) (GB)
- Takeda (Japan) (JP)
- Imperial College London (GB)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1002/ana.78116
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Allergan